More Articles

Fujifilm and Kyowa launch biosimilars joint venture Biosimilars/News | Posted 30/03/2012

The Japanese digital camera maker Fujifilm Corporation (Fujifilm) and biotech firm Kyowa Hakko Kirin (Kyowa) announced on 27 March 2012 that they have launched their biosimilars joint venture, whic...

Also noted on generics: 30 March 2012 Generics/General | Posted 30/03/2012

Watson in talks to buy ActavisUS generics manufacturer Watson is rumoured to be making a bid for Icelandic generics company Actavis, according to Bloomberg, creating one of the world’s largest gen...

FDA announces public hearing on biosimilars’ guidelines Biosimilars/General | Posted 23/03/2012

FDA has announced a one-day public hearing to be held on 11 May 2012, in Silver Spring, Maryland, USA. During the meeting FDA hopes ‘to obtain input on recently issued draft guidelines relating to...

Pricing of biosimilars Biosimilars/Research | Posted 23/03/2012

For small molecule generics, reductions in price of around 80% have been observed after the first six months to a year of generics entry to the market in countries such as Germany, UK and the US [1...

Generic rosuvastatin approved in Canada Generics/News | Posted 23/03/2012

Generics giant Mylan Pharmaceuticals (Mylan) announced on 15 March 2012 that it had received approval from Health Canada for a generic version of AstraZeneca’s leading cholesterol drug Crestor (ros...

Brand-name atorvastatin cheaper than generics Generics/Research | Posted 23/03/2012

Despite generics of Pfizer’s blockbuster cholesterol-reducing drug Lipitor (atorvastatin) being available in the US since the patent expired in November 2011, many patients are still receiving the...

Dr Reddy’s looks to biosimilars for growth Biosimilars/News | Posted 23/03/2012

Generics giant Dr Reddy’s Laboratories (Dr Reddy’s) has been betting big on biosimilars and it seems that the risk is paying off, as the company announced record profits for the last quarter of 2011.

AstraZeneca sues FDA over generic quetiapine Generics/News | Posted 23/03/2012

In an attempt to prevent competition from generics to its blockbuster anti-psychotic drug Seroquel (quetiapine fumarate), pharma giant AstraZeneca has filed a lawsuit against FDA.